Skip to main content

Table 4 EORTC QLQ-H&N35 scoring at the onset and end of assessment in 17 H&N PGL patients

From: Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Variables Baseline QLQ Post-therapy QLQ P value
Pain 51.8 ± 22.7 26.8 ± 20.8 0.001
Swallowing 31.4 ± 33.3 17.31 ± 16.6 0.001
Senses (taste and smell) 11.1 ± 24.9 10.1 ± 24.3 0.903
Speech 34.5 ± 22.2 30.2 ± 22.2 0.296
Social eating 31.1 ± 33.3 16.6 ± 16.6 0.002
Social contact 29.6 ± 23.7 19.6 ± 19.5 0.074
Sexuality 28.7 ± 25 31.4 ± 16.6 0.562
Teeth 25.9 ± 33.3 16.6 ± 0.1 0.244
Opening mouth 44.4 ± 50 24 ± 33.3 0.158
Dry mouth 18.5 ± 33.3 11.1 ± 0.1 0.125
Sticky saliva 11.1 ± 16 3.7 ± 10.7 0.112
Coughing 38.8 ± 33.3 20.3 ± 16.6 0.042
Felt ill 48.1 ± 26.1 27.7 ± 32.8 0.046
Painkiller 83.3 ± 38.3 18.5 ± 17 0.000
Nutritional supplement 44.4 ± 51.5 18.6 ± 12.7 0.046